Hudson Bay Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hudson Bay Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$45.3M	–	1619
2025 Q4	$45.3M	Buy	+100,000	New	+$43.1M	0.15%	127
2025 Q3	–	Sell	-8,100	Closed	-$3.61M	–	1711
2025 Q2	$3.61M	Sell	8,100 -41,700	-84%	-$19.2M	0.01%	634
2025 Q1	$24.1M	Buy	+49,800	New	+$23.2M	0.07%	236
2024 Q3	–	Sell	-137,500	Closed	-$64.4M	–	1055
2024 Q2	$64.4M	Buy	+137,500	New	+$59.7M	0.3%	63
2024 Q1	–	Sell	-42,000	Closed	-$17.1M	–	892
2023 Q4	$17.1M	Buy	42,000 +35,000	+500%	+$12.9M	0.11%	117
2023 Q3	$2.43M	Buy	+7,000	New	+$2.45M	0.02%	444
2019 Q2	–	Sell	-61,000	Closed	-$11.2M	–	713
2019 Q1	$11.2M	Buy	61,000 +22,300	+58%	+$4.12M	0.14%	137
2018 Q4	$6.41M	Buy	+38,700	New	+$6.71M	0.09%	221
2017 Q2	–	Sell	-86,500	Closed	-$9.46M	–	813
2017 Q1	$9.46M	Buy	+86,500	New	+$7.62M	0.13%	167

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hudson Bay Capital Management's VRTX Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 73% in Q1 2026, selling an estimated $55.7M and leaving 45,000 shares worth $20.1M. The position accounts for 0.07% of the portfolio, ranked #185.

Hudson Bay Capital Management first reported a position in VRTX in Q1 2017 and has held it in 24 quarters since. The position peaked at $74.6M in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Hudson Bay Capital Management held 45,000 shares of Vertex Pharmaceuticals worth $20.1M as of Q1 2026.
Hudson Bay Capital Management sold 119,518 Vertex Pharmaceuticals shares in Q1 2026, an estimated $55.7M.
Vertex Pharmaceuticals made up 0.07% of Hudson Bay Capital Management's portfolio in Q1 2026, its #185 holding.
Hudson Bay Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 24 quarters since.
Hudson Bay Capital Management's Vertex Pharmaceuticals position peaked at $74.6M in Q4 2025.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.